|
Volumn 189, Issue 6, 2004, Pages 964-970
|
A 48-week duration of therapy with pegylated interferon α2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CREATINE;
REBETRON;
ADULT;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COVARIANCE;
CREATININE CLEARANCE;
DATA BASE;
DIAGNOSTIC ACCURACY;
DISEASE SIMULATION;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG EXCRETION;
FEMALE;
FOLLOW UP;
HEPATITIS C;
HUMAN;
INFORMATION RETRIEVAL;
MAJOR CLINICAL STUDY;
MALE;
PREDICTION;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
VIRUS DETECTION;
VIRUS GENOME;
VIRUS ISOLATION;
VIRUS LOAD;
DRUG THERAPY, COMBINATION;
GENOTYPE;
HEPACIVIRUS;
HEPATITIS C;
HUMANS;
INTERFERON ALFA-2A;
INTERFERON ALFA-2B;
POLYETHYLENE GLYCOLS;
PROBABILITY;
RIBAVIRIN;
RNA, VIRAL;
TIME FACTORS;
VIRAL LOAD;
|
EID: 1642328395
PISSN: 00221899
EISSN: None
Source Type: Journal
DOI: 10.1086/382279 Document Type: Article |
Times cited : (80)
|
References (8)
|